Challenges in Vaccine Development: The Case of Moderna's mRNA Influenza Vaccine and FDA Rejection
Moderna, a pharmaceutical company, proposed testing its new mRNA influenza vaccine with the FDA in April 2024. The plan involved dividing 40,000 subjects in 11 countries into two groups, with one group receiving the mRNA flu vaccine and the other a standard-dose flu vaccine. The FDA suggested comparing the mRNA vaccine to a high-dose flu vaccine for people over 65, as recommended by the CDC. Despite this, Moderna proceeded with the trial, knowing it might not receive a CDC recommendation for older subjects but that the FDA would still review the submission.
In September 2024, Moderna initiated a vaccine trial with 40,700 subjects, half of whom received the mRNA flu vaccine and the other half the standard-dose vaccine. The mRNA vaccine demonstrated 27% greater effectiveness in preventing symptomatic flu cases and 49% greater effectiveness against hospitalization compared to the standard-dose flu vaccine. The FDA supported the trial design in August 2025 and encouraged Moderna to apply for licensure based on the positive results, including higher antibody levels in people over 65.
However, on February 3, 2026, the FDA, under Vinay Prasad's leadership, refused to review Moderna's application for licensure of its mRNA influenza vaccine, despite previous written agreements. This decision was seen as arbitrary and inconsistent with the agency's previous communications. The refusal to review the application raised concerns about potential political influences affecting public health decisions.
The rejection of Moderna's mRNA influenza vaccine by the FDA, led by Vinay Prasad, is viewed as part of a broader campaign against mRNA vaccines, spearheaded by RFK Jr. RFK Jr. has been critical of mRNA COVID vaccines and has withdrawn funding for research on an mRNA bird flu vaccine. The influence of individuals like RFK Jr. and Robert Malone, who advocate against mRNA vaccines, on public health decisions is concerning and may hinder the development of innovative vaccines.
The arbitrary decisions made by the FDA, influenced by individuals with anti-mRNA vaccine sentiments, could deter pharmaceutical companies from pursuing advancements in vaccine technology. This trend is worrying as it may impede the progress towards developing more effective vaccines for public health. The need for transparent and evidence-based decision-making in regulatory processes is crucial to ensure the safety and efficacy of vaccines for the population.